English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/61828
Share/Impact:
Statistics
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:

Title

Multiple myeloma treatment strategies with novel agents in 2011: A European perspective

AuthorsLudwig, Heinz; Bladé, Joan; San Miguel, Jesús F.
Issue Date2011
PublisherAlphaMed Press
CitationOncologist 16(4): 388-403 (2011)
AbstractThe arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices. © AlphaMed Press.
URIhttp://hdl.handle.net/10261/61828
DOI10.1634/theoncologist.2010-0386
Identifiersdoi: 10.1634/theoncologist.2010-0386
issn: 1083-7159
e-issn: 1549-490X
Appears in Collections:(IBMCC) Artículos
Files in This Item:
File Description SizeFormat 
accesoRestringido.pdf15,38 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work
 

Related articles:


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.